Jennifer Brigitte Green

Professor of Medicine

Medicine, Endocrinology, Metabolism, and Nutrition

jennifer.green@duke.edu

Duke Box 3850, Durham, NC 27715

Durham Centre, Room 641, P.O. Box 17969, Durham, NC 27715

More About This Person

At a Glance

Credentials
1. Education
2. Licensure

Academic Experience

Global Scholarship

Keywords

Research

Scholarly Works

Teaching & Mentoring

Recognition
1. Academic Honors
2. News Items

Professional Activities

Embed Profile Data

Embed Profile Data

Scholarly Works - Conferences

Simultaneous initiation of finerenone and empagliflozin by baseline glucagon-like peptide-1 receptor agonist use: a prespecified analysis of CONFIDENCE

Conference DIABETOLOGIA · September 2025 Link to item Cite

CONFIDENCE Asia: effect of simultaneous initiation of finerenone and empagliflozin on urinary albumin-to-creatinine ratio in Asian participants from the CONFIDENCE trial

Conference DIABETOLOGIA · September 2025 Link to item Cite

PERSISTENCE AND DISCONTINUATION OF SGLT-2I AND GLP-1RA AMONG PERSONS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE TREATED IN US CARDIOLOGY CLINICS: INSIGHTS FROM THE COORDINATE-DIABETES TRIAL

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · April 2, 2024 Link to item Cite

CHARACTERISTICS OF PERSONS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PRESCRIBED SGLT-2I AND/OR GLP-1RA AMONG CARDIOLOGY CLINICS IN THE US: INSIGHTS FROM A LARGE IMPLEMENTATION TRIAL

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · April 2, 2024 Link to item Cite

INTERVENTION TO IMPROVE GUIDELINE-BASED CARE FOR DIABETES AND CARDIOVASCULAR DISEASE IS EFFECTIVE IN BLACK AND HISPANIC POPULATIONS

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · April 2, 2024 Link to item Cite

ALBIGLUTIDE AND ATRIAL FIBRILLATION/ATRIAL FLUTTER IN PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE - A SECONDARY ANALYSIS OF THE HARMONY OUTCOMES TRIAL

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · April 2, 2024 Link to item Cite

Uric Acid and Treatment With Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF): the EMPEROR-Preserved Trial

Conference Metabolism · May 2023 Full text Cite

PROTEOMIC MARKERS OF CARDIAC FIBROSIS AND ENDOTHELIAL FUNCTION ASSOCIATED WITH HEART FAILURE IN PATIENTS WITH DIABETES: AN EXSCEL BIOMARKER SUB-STUDY

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 7, 2023 Link to item Cite

EFFECTS OF ALBIGLUTIDE ON TYPES AND NUMBERS OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE IN THE HARMONY OUTCOMES TRIAL

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 7, 2023 Link to item Cite

Impact of empagliflozin on insulin use in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes: sub-analysis from EMPEROR-Preserved trial

Conference DIABETOLOGIA · September 2022 Link to item Cite

Cardiorenal and safety outcomes with finerenone in patients with obesity, CKD and type 2 diabetes

Conference DIABETOLOGIA · September 2022 Link to item Cite

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.

Conference Diabetes Care · January 1, 2022 OBJECTIVE: Phenotypic heterogeneity among patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) is ill defined. We used cluster analysis machine-learning algorithms to identify phenotypes among trial participants ... Full text Link to item Cite

Clinical Outcomes with Metformin and Sulfonylurea Initiation Among Patients with Heart Failure and Diabetes: From Get with the Guidelines-Heart Failure

Conference CIRCULATION · November 16, 2021 Link to item Cite

ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

Diabetes is Associated with Worse In-Hospital and 30-Day Post-Discharge Morbidity in Patients with Heart Failure with Preserved Ejection Fraction: Findings from the Get With The Guidelines Heart Failure Registry

Conference Journal of Cardiac Failure · August 2018 Full text Cite

LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

UNDETERMINED CAUSE OF DEATH: A POOLED ANALYSIS OF 9,307 DEATHS ACROSS 9 CARDIOVASCULAR TRIALS

Conference Journal of the American College of Cardiology · March 2018 Full text Cite

International Variation in Management and Clinical Outcome of Patients With Type 2 Diabetes and Heart Failure: Insights From TECOS

Conference CIRCULATION · November 14, 2017 Link to item Cite

Underuse of Oral Anticoagulation, High Use of Aspirin and Worse Clinical Outcomes in Patients With Type 2 Diabetes and Atrial Fibrillation: Insights From the TECOS Trial

Conference CIRCULATION · November 14, 2017 Link to item Cite

Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Conference DIABETOLOGIA · September 1, 2017 Link to item Cite

Time to insulin in the Trial Evaluating Cardiovascular Outomes with Sitagliptin (TECOS)

Conference DIABETOLOGIA · September 1, 2017 Link to item Cite

Risk of pancreatic diseases by second-line anti diabetes drug class: real world based evidence

Conference DIABETOLOGIA · September 1, 2017 Link to item Cite

The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial

Conference EUROPEAN HEART JOURNAL · August 1, 2017 Link to item Cite

Medical Resource Use and Costs in Patients with Type 2 Diabetes Mellitus during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Conference DIABETES · June 1, 2017 Link to item Cite

Emerging Sitagliptin Benefit for All-Cause Hospitalizations: Evidence from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Conference DIABETES · June 1, 2017 Link to item Cite

Sex differences in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Conference DIABETOLOGIA · August 1, 2016 Link to item Cite

Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial

Conference DIABETOLOGIA · August 1, 2016 Link to item Cite

Physician and Site Characteristics May Influence the Propensity to Prescribe Aspirin and Statin for Patients with Type 2 Diabetes at High Risk of Cardiovascular Disease: Insights from TECOS Trial Investigator Survey

Conference DIABETES · June 2014 Link to item Cite

DIABETIC PATIENTS HAVE SIMILAR VEIN GRAFT FAILURE AT 1 YEAR, BUT HIGHER 5-YEAR MORTALITY THAN NON-DIABETIC PATIENTS UNDERGOING CORONARY ARTERY BYPASS SURGERY: INSIGHTS FROM THE PREVENT-IV TRIAL

Conference Journal of the American College of Cardiology · March 2012 Full text Cite

Successful transitions from MDI therapy to sensor-augmented pump therapy in the STAR 3 study: system settings and behaviours

Conference DIABETOLOGIA · September 1, 2011 Featured Work Link to item Cite

Glycaemia management of minority participants in ACCORD

Conference DIABETOLOGIA · September 1, 2010 Link to item Cite

Glucose control in adults during a 1-year randomised controlled trial comparing sensor-augmented pump therapy and multiple daily injection therapy: STAR 3 study

Conference DIABETOLOGIA · September 1, 2010 Link to item Cite

Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Conference DIABETOLOGIA · September 1, 2009 Link to item Cite